medGadget -- A collaboration of Australian scientists has identified a new imaging radiotracer as an excellent PET contrast agent for melanoma in laboratory mice. The so called [18F]N-(2-(Diethylamino)ethyl)-6-fluoronicotinamide is now scheduled to begin clinical trials sometime next year, according to the press release by the American Chemical Society.
